Search

Your search keyword '"Szymonifka, Jackie"' showing total 493 results
Start Over Author "Szymonifka, Jackie"
493 results on '"Szymonifka, Jackie"'

2. Validation of the Hip Disability and Osteoarthritis Outcome Score and Knee Injury and Osteoarthritis Outcome Score Pain and Function Subscales for Use in Total Hip Replacement and Total Knee Replacement Clinical Trials

Author

Goodman, Susan M., Mehta, Bella Y., Mandl, Lisa A., Szymonifka, Jackie D., Finik, Jackie, Figgie, Mark P., Navarro-Millán, Iris Y., Bostrom, Mathias P., Parks, Michael L., Padgett, Douglas E., McLawhorn, Alexander S., Antao, Vinicius C., Yates, Adolph J., Springer, Bryan D., Lyman, Stephen L., and Singh, Jasvinder A.

Published
2020
Full Text
View/download PDF

4. Coronary sinus biomarker sampling compared to peripheral venous blood for predicting outcomes in patients with severe heart failure undergoing cardiac resynchronization therapy: The BIOCRT study

Author

Truong, Quynh A, Januzzi, James L, Szymonifka, Jackie, Thai, Wai-ee, Wai, Bryan, Lavender, Zachary, Sharma, Umesh, Sandoval, Ryan M, Grunau, Zachary S, Basnet, Sandeep, Babatunde, Adefolakemi, Ajijola, Olujimi A, Min, James K, and Singh, Jagmeet P

Subjects
Clinical Research, Cardiovascular, Heart Disease, Detection, screening and diagnosis, 4.1 Discovery and preclinical testing of markers and technologies, 4.2 Evaluation of markers and technologies, Aged, Aged, 80 and over, Biomarkers, Blood Specimen Collection, Cardiac Resynchronization Therapy, Coronary Sinus, Female, Follow-Up Studies, Galectin 3, Heart Failure, Humans, Male, Middle Aged, Natriuretic Peptide, Brain, Peptide Fragments, Predictive Value of Tests, Prospective Studies, Risk Assessment, Severity of Illness Index, Survival Rate, Treatment Outcome, Veins, Biomarker, Coronary sinus, Galectin-3, Soluble 512, Cardiac resynchronization therapy, Soluble ST2, Biomedical Engineering, Cardiorespiratory Medicine and Haematology, Cardiovascular System & Hematology
Abstract

BackgroundA significant minority of patients receiving cardiac resynchronization therapy (CRT) remain nonresponsive to this intervention.ObjectiveThis study aimed to determine whether coronary sinus (CS) or baseline peripheral venous (PV) levels of established and emerging heart failure (HF) biomarkers are predictive of CRT outcomes.MethodsIn 73 patients (aged 68 ± 12 years; 83% men; ejection fraction 27% ± 7%) with CS and PV blood samples drawn simultaneously at the time of CRT device implantation, we measured amino-terminal pro-B-type natriuretic peptide (NT-proBNP), galectin-3 (gal-3), and soluble ST2 (sST2) levels. NT-proBNP concentrations >2000 pg/mL, gal-3 concentrations >25.9 ng/mL, and sST2 concentrations >35 ng/mL were considered positive on the basis of established PV cut points for identifying "high-risk" individuals with HF. CRT response was adjudicated by the HF Clinical Composite Score. A major adverse cardiovascular event (MACE) was defined as the composite end point of death, cardiac transplant, left ventricular assist device, and HF hospitalization at 2 years.ResultsNT-proBNP concentrations were 20% higher in the CS than in the periphery, while gal-3 and sST2 concentrations were 10% higher in the periphery than in the CS (all P < .001). There were 45% CRT nonresponders at 6 months and 16 (22%) patients with MACE. Triple-positive CS values yielded the highest specificity of 95% for predicting CRT nonresponse. Consistently, CS strategies identified patients at higher risk of developing MACE, with >11-fold adjusted increase for triple-positive CS patients compared to triple-negative patients (all P ≤ .04). PV strategies were not predictive of MACE.ConclusionOur findings suggest that CS sampling of HF biomarkers may be better than PV sampling for predicting CRT outcomes. Larger studies are needed to confirm our findings.

Published
2014

11. Supplementary Table 1 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1

Author

Heuck, Christoph J., primary, Szymonifka, Jackie, primary, Hansen, Emily, primary, Shaughnessy, John D., primary, Usmani, Saad Z., primary, van Rhee, Frits, primary, Anaissie, Elias, primary, Nair, Bijay, primary, Waheed, Sarah, primary, Alsayed, Yazan, primary, Petty, Nathan, primary, Bailey, Clyde, primary, Epstein, Joshua, primary, Hoering, Antje, primary, Crowley, John, primary, and Barlogie, Bart, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figure 1 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1

Author

Heuck, Christoph J., primary, Szymonifka, Jackie, primary, Hansen, Emily, primary, Shaughnessy, John D., primary, Usmani, Saad Z., primary, van Rhee, Frits, primary, Anaissie, Elias, primary, Nair, Bijay, primary, Waheed, Sarah, primary, Alsayed, Yazan, primary, Petty, Nathan, primary, Bailey, Clyde, primary, Epstein, Joshua, primary, Hoering, Antje, primary, Crowley, John, primary, and Barlogie, Bart, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure 2 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1

Author

Heuck, Christoph J., primary, Szymonifka, Jackie, primary, Hansen, Emily, primary, Shaughnessy, John D., primary, Usmani, Saad Z., primary, van Rhee, Frits, primary, Anaissie, Elias, primary, Nair, Bijay, primary, Waheed, Sarah, primary, Alsayed, Yazan, primary, Petty, Nathan, primary, Bailey, Clyde, primary, Epstein, Joshua, primary, Hoering, Antje, primary, Crowley, John, primary, and Barlogie, Bart, primary

Published
2023
Full Text
View/download PDF

15. Supplementary Figure 3 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1

Author

Heuck, Christoph J., primary, Szymonifka, Jackie, primary, Hansen, Emily, primary, Shaughnessy, John D., primary, Usmani, Saad Z., primary, van Rhee, Frits, primary, Anaissie, Elias, primary, Nair, Bijay, primary, Waheed, Sarah, primary, Alsayed, Yazan, primary, Petty, Nathan, primary, Bailey, Clyde, primary, Epstein, Joshua, primary, Hoering, Antje, primary, Crowley, John, primary, and Barlogie, Bart, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Figure Legend from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1

Author

Heuck, Christoph J., primary, Szymonifka, Jackie, primary, Hansen, Emily, primary, Shaughnessy, John D., primary, Usmani, Saad Z., primary, van Rhee, Frits, primary, Anaissie, Elias, primary, Nair, Bijay, primary, Waheed, Sarah, primary, Alsayed, Yazan, primary, Petty, Nathan, primary, Bailey, Clyde, primary, Epstein, Joshua, primary, Hoering, Antje, primary, Crowley, John, primary, and Barlogie, Bart, primary

Published
2023
Full Text
View/download PDF

17. Supplementary Figure 4 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1

Author

Heuck, Christoph J., primary, Szymonifka, Jackie, primary, Hansen, Emily, primary, Shaughnessy, John D., primary, Usmani, Saad Z., primary, van Rhee, Frits, primary, Anaissie, Elias, primary, Nair, Bijay, primary, Waheed, Sarah, primary, Alsayed, Yazan, primary, Petty, Nathan, primary, Bailey, Clyde, primary, Epstein, Joshua, primary, Hoering, Antje, primary, Crowley, John, primary, and Barlogie, Bart, primary

Published
2023
Full Text
View/download PDF

18. Supplementary Figure 5 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1

Author

Heuck, Christoph J., primary, Szymonifka, Jackie, primary, Hansen, Emily, primary, Shaughnessy, John D., primary, Usmani, Saad Z., primary, van Rhee, Frits, primary, Anaissie, Elias, primary, Nair, Bijay, primary, Waheed, Sarah, primary, Alsayed, Yazan, primary, Petty, Nathan, primary, Bailey, Clyde, primary, Epstein, Joshua, primary, Hoering, Antje, primary, Crowley, John, primary, and Barlogie, Bart, primary

Published
2023
Full Text
View/download PDF

26. Basic Statistics

Author

Szymonifka, Jackie, Healy, Brian C., Gaggin, Hanna K., editor, and Januzzi, Jr., James L., editor

Published
2014
Full Text
View/download PDF

32. Spatial environmental factors predict cardiovascular and all-cause mortality: Results of the SPACE study

Author

Hadley, Michael B., primary, Nalini, Mahdi, additional, Adhikari, Samrachana, additional, Szymonifka, Jackie, additional, Etemadi, Arash, additional, Kamangar, Farin, additional, Khoshnia, Masoud, additional, McChane, Tyler, additional, Pourshams, Akram, additional, Poustchi, Hossein, additional, Sepanlou, Sadaf G., additional, Abnet, Christian, additional, Freedman, Neal D., additional, Boffetta, Paolo, additional, Malekzadeh, Reza, additional, and Vedanthan, Rajesh, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results